ANTI-SMITH ANTIBODIES INFLUENCE ON CLINICAL, BIOLOGICAL AND IMMUNOLOGICAL FEATURES OF SYSTEMIC LUPUS ERYTHEMATOSUS IN TUNISIAN PATIENTS

T Ben Salem, M Tougorti, I Naceur, I Ben Ghorbel, M Lamloum, MH Houman. Department of Internal Medicine, La Rabta University Hospital, Tunis, Tunisia

10.1136/lupus-2018-abstract.85

Background Anti-Smith (Sm) antibodies are highly specific for systemic lupus erythematosus (SLE), their associations with some organ involvements were described.

Objectives The aim of our study was to determine clinical, biological and immunological characteristics in SLE patients according to the presence of anti-Sm antibodies.

Methods A retrospective study of a group of Tunisian patients with SLE (fulfilling the ACR revised criteria) was conducted in an internal medicine department. Patients were divided in two groups according to the presence (group 1) or not (group 2) of anti-Sm antibodies. Variables with a p inferior to 0.05 were considered to be statistically significant.

Results Anti-Sm antibodies were screened in 153 among 246 SLE patients and were positive in 64% of patients. Mean age at SLE diagnosis was significantly lower in the group 1 (31.82 years ± 12.70 vs 36.16 years ± 12.34; p = 0.0043). Poor general state was the only clinical feature significantly more frequent in group 1 (54.2% vs 36.5%; p<0.04). Lupus nephritis was more frequent in patients with anti-Sm antibodies without significant difference (47.9% vs 38.2%; p = 0.24). Arthritis were more frequent in group 2 (42.6% vs 50%; p = 0.38). Central nervous system manifestations (16.7% vs 16.4%), pericarditis (36.1% vs 31.4%) and pleural effusion (23.4% vs 27.8%) were similar in the two groups. Anemia (77.1% vs 74.5; p = 0.7), leucopenia (49% vs 47.2%; p = 0.8) and thrombocytopenia (26% vs 15%; p = 0.12) were more frequent in patients with anti-Sm antibodies without significant differences. Anti-Sm antibodies were significantly associated with anti-RNP antibodies (78.6% vs 17.6%; p < 0.0001). Remission was less frequent is group 1 (70.4% vs 82.9%; p = 0.14) and death was more frequent in this group (16% vs 10.3%; p = 0.4) without significant differences.

Conclusions In our patients, anti-Sm antibodies prevalence was higher than those reported in other cohorts (5% to 49%). Patients with anti-Sm antibodies seem to develop clinical SLE manifestations earlier than other patients. In our study, anti-Sm antibodies doesn’t influence SLE clinical course and weren’t associated with hematologic disorders, whereas in another series, anti-Sm antibodies were associated with lupus nephritis, serositis, anaemia and leucopenia.

PS2:39 GENETIC AND ENVIRONMENTAL RISK FACTORS FOR SYSTEMIC LUPUS ERYTHEMATOSUS – A NATIONWIDE POPULATION STUDY

1^H Leffens, 2S Jacobsen, 3H Ullum, 4T Lange. 1Copenhagen Lupus and Vasculitis Clinic, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 2DANBio, Copenhagen, Denmark; 3Department of Clinical Immunology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark; 4Section of Biostatistics, Copenhagen University, Copenhagen, Denmark

10.1136/lupus-2018-abstract.87

Purpose Environmental- and genetic factors’ influence in the pathogenesis of rheumatic disease including systemic lupus erythematosus (SLE) have individually been extensively researched. Moreover, a synergistic effect of smoking with anti-citrullinated protein has been established for the risk of developing rheumatoid arthritis. In SLE, however, studies on synergistic effect are few and of limited sample size. We aim to investigate if established genetic and environmental risk factors for SLE display additive or synergistic interactions on the risk of SLE.

Methods A case-control designed nationwide epidemiological study of Danish patients with SLE will be conducted. Patient data/analysis of a peripheral lymphoid organ (spleen) and end-organ tissues (kidneys, brain) of lupus-prone and healthy mice.

Methods NZB/W-F1 lupus-prone mice were sacrificed at the pre-puberty, pre-autoimmunity and nephritic stage of the disease. Age-matched C57/BL6 mice were used as controls. Spleen, kidneys and brain were removed and total RNA was extracted. Paired-end RNA-sequencing was performed with Illumina HiSeq 2000 platform. Relative expression levels of transcripts and differentially expressed genes (DEG) (FC > 1.5, p < 0.05) were calculated. Functional enrichment analysis was performed with IPA, RNEA and gprofiler.